1
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Liu Y, Zhang Y, Jia K, Dong Y and Ma W:
Metformin inhibits the proliferation of A431 cells by modulating
the PI3K/Akt signaling pathway. Exp Ther Med. 9:1401–1406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Pappalardo F, Russo G, Candido S, Pennisi
M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F and Libra M:
Computational modeling of PI3K/AKT and MAPK signaling pathways in
melanoma cancer. PLoS One. 11:e01521042016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Vujic I, Sanlorenzo M, Posch C,
Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger
K and Ortiz-Urda S: Metformin and trametinib have synergistic
effects on cell viability and tumor growth in NRAS mutant cancer.
Oncotarget. 6:969–978. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ashcroft M, Ludwig RL, Woods DB, Copeland
TD, Weber HO, MacRae EJ and Vousden KH: Phosphorylation of HDM2 by
Akt. Oncogene. 21:1955–1962. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Dong C, Zhao B, Long F, Liu Y, Liu Z, Li
S, Yang X, Sun D, Wang H, Liu Q, et al: Nogo-B receptor promotes
the chemoresistance of human hepatocellular carcinoma via the
ubiquitination of p53 protein. Oncotarget. 7:8850–8865. 2016.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Würth R, Pattarozzi A, Gatti M, Bajetto A,
Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, et al:
Metformin selectively affects human glioblastoma tumor-initiating
cell viability: A role for metformin-induced inhibition of Akt.
Cell Cycle. 12:145–156. 2013. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
13
|
He G, Zhang YW, Lee JH, Zeng SX, Wang YV,
Luo Z, Dong XC, Viollet B, Wahl GM and Lu H: AMP-activated protein
kinase induces p53 by phosphorylating MDMX and inhibiting its
activity. Mol Cell Biol. 34:148–157. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang H, Ma X, Ren S, Buolamwini JK and Yan
C: A small-molecule inhibitor of MDMX activates p53 and induces
apoptosis. Mol Cancer Ther. 10:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ravishankar D, Rajora AK, Greco F and
Osborn HM: Flavonoids as prospective compounds for anti-cancer
therapy. Int J Biochem Cell Biol. 45:2821–2831. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sak K: Cytotoxicity of dietary flavonoids
on different human cancer types. Pharmacogn Rev. 8:122–146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kim SJ, Kim HJ, Kim HR, Lee SH, Cho SD,
Choi CS, Nam JS and Jung JY: Antitumor actions of baicalein and
wogonin in HT-29 human colorectal cancer cells. Mol Med Rep.
6:1443–1449. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Koosha S, Alshawsh MA, Looi CY, Seyedan A
and Mohamed Z: An association map on the effect of flavonoids on
the signaling pathways in colorectal cancer. Int J Med Sci.
13:374–385. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Hirano T, Abe K, Gotoh M and Oka K: Citrus
flavone tangeretin inhibits leukaemic HL-60 cell growth partially
through induction of apoptosis with less cytotoxicity on normal
lymphocytes. Br J Cancer. 72:1380–1388. 1995. View Article : Google Scholar : PubMed/NCBI
|
20
|
Iakovleva I, Begum A, Pokrzywa M,
Walfridsson M, Sauer-Eriksson AE and Olofsson A: The flavonoid
luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin
mediated toxic response. PLoS One. 10:e01282222015. View Article : Google Scholar : PubMed/NCBI
|
21
|
El-Naga RN: Pre-treatment with cardamonin
protects against cisplatin-induced nephrotoxicity in rats: Impact
on NOX-1, inflammation and apoptosis. Toxicol Appl Pharmacol.
274:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wenzel U, Kuntz S, Brendel MD and Daniel
H: Dietary flavone is a potent apoptosis inducer in human colon
carcinoma cells. Cancer Res. 60:3823–3831. 2000.PubMed/NCBI
|
23
|
Herzog A, Kindermann B, Döring F, Daniel H
and Wenzel U: Pleiotropic molecular effects of the pro-apoptotic
dietary constituent flavone in human colon cancer cells identified
by protein and mRNA expression profiling. Proteomics. 4:2455–2464.
2004. View Article : Google Scholar : PubMed/NCBI
|
24
|
Lin CH, Chang CY, Lee KR, Lin HJ, Chen TH
and Wan L: Flavones inhibit breast cancer proliferation through the
Akt/FOXO3a signaling pathway. BMC cancer. 15:9582015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ
and Dennis PA: Repositioning metformin for cancer prevention and
treatment. Trends Endocrinol Metab. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Cerezo M, Tomic T, Ballotti R and Rocchi
S: Is it time to test biguanide metformin in the treatment of
melanoma? Pigment Cell Melanoma Res. 28:8–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Mamane Y, Petroulakis E, Rong L, Yoshida
K, Ler LW and Sonenberg N: eIF4E-from translation to
transformation. Oncogene. 23:3172–3179. 2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Chou CC, Lee KH, Lai IL, Wang D, Mo X,
Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal
phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a
signaling axis. Cancer Res. 74:4783–4795. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Franzen CA, Amargo E, Todorović V, Desai
BV, Huda S, Mirzoeva S, Chiu K, Grzybowski BA, Chew TL, Green KJ
and Pelling JC: The chemopreventive bioflavonoid apigenin inhibits
prostate cancer cell motility through the focal adhesion kinase/Src
signaling mechanism. Cancer Prev Res (Phila). 2:830–841. 2009.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Shukla S, Bhaskaran N, Babcook MA, Fu P,
Maclennan GT and Gupta S: Apigenin inhibits prostate cancer
progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Carcinogenesis. 35:452–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhu W, Yang B, Fu H, Ma L, Liu T, Chai R,
Zheng Z, Zhang Q and Li G: Flavone inhibits nitric oxide synthase
(NOS) activity, nitric oxide production and protein S-nitrosylation
in breast cancer cells. Biochem Biophys Res Commun. 458:590–595.
2015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Seo YJ, Kim BS, Chun SY, Park YK, Kang KS
and Kwon TG: Apoptotic effects of genistein, biochanin-A and
apigenin on LNCaP and PC-3 cells by p21 through transcriptional
inhibition of polo-like kinase-1. J Korean Med Sci. 26:1489–1494.
2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Dey N, De P and Leyland-Jones B:
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell
signaling to clinical trials. Pharmacol Ther. 175:91–106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
36
|
Ling X, Xu C, Fan C, Zhong K, Li F and
Wang X: FL118 induces p53-dependent senescence in colorectal cancer
cells by promoting degradation of MdmX. Cancer Res. 74:7487–7497.
2014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhang X, Wu H, Liu C, Tian J and Qu L:
PI3K/Akt/p53 pathway inhibits reovirus infection. Infect Genet
Evol. 34:415–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
38
|
Ben-Sahra I, Dirat B, Laurent K, Puissant
A, Auberger P, Budanov A, Tanti JF and Bost F: Sestrin2 integrates
Akt and mTOR signaling to protect cells against energetic
stress-induced death. Cell Death Differ. 20:611–619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Li T: Pacilitaxel induces human
nasopharyngeal carcinoma cell line CNE2 apoptosis and growth
inhibition by suppressing PI3K/AKT/p53 signaling pathway. Lin Chung
Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 29:2147–2150. 2015.(In
Chinese). PubMed/NCBI
|
40
|
Chipuk JE, Kuwana T, Bouchier-Hayes L,
Droin NM, Newmeyer DD, Schule M and Green DR: Direct activation of
Bax by p53 mediates mitochondrial membrane permeabilization and
apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
41
|
Miyashita T, Krajewski S, Krajewska M,
Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor
suppressor p53 is a regulator of bcl-2 and bax gene expression in
vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
|
42
|
Zhong LR, Chen X and Wei KM: Radix
tetrastigma hemsleyani flavone induces apoptosis in human lung
carcinoma a549 cells by modulating the MAPK pathway. Asian Pac J
Cancer Prev. 14:5983–5987. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Lucas CD, Allen KC, Dorward DA, Hoodless
LJ, Melrose LA, Marwick JA, Tucker CS, Haslett C, Duffin R and
Rossi AG: Flavones induce neutrophil apoptosis by down-regulation
of Mcl-1 via a proteasomal-dependent pathway. FASEB J.
27:1084–1094. 2013. View Article : Google Scholar : PubMed/NCBI
|